CVS Health Corp (CVS) Shares Bought by Dai Ichi Life Insurance Company Ltd

Dai Ichi Life Insurance Company Ltd grew its stake in shares of CVS Health Corp (NYSE:CVS) by 65.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,965 shares of the pharmacy operator’s stock after buying an additional 30,000 shares during the period. Dai Ichi Life Insurance Company Ltd’s holdings in CVS Health were worth $6,177,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nuance Investments LLC lifted its position in CVS Health by 19.9% in the third quarter. Nuance Investments LLC now owns 44,314 shares of the pharmacy operator’s stock valued at $3,604,000 after purchasing an additional 7,358 shares during the last quarter. Evergreen Capital Management LLC raised its holdings in shares of CVS Health by 3.7% during the third quarter. Evergreen Capital Management LLC now owns 36,576 shares of the pharmacy operator’s stock valued at $2,974,000 after acquiring an additional 1,297 shares in the last quarter. Richard C. Young & CO. LTD. raised its holdings in shares of CVS Health by 3.3% during the third quarter. Richard C. Young & CO. LTD. now owns 89,423 shares of the pharmacy operator’s stock valued at $7,272,000 after acquiring an additional 2,880 shares in the last quarter. Reynders McVeigh Capital Management LLC raised its holdings in shares of CVS Health by 0.6% during the third quarter. Reynders McVeigh Capital Management LLC now owns 344,043 shares of the pharmacy operator’s stock valued at $27,978,000 after acquiring an additional 2,157 shares in the last quarter. Finally, Iberiabank Corp raised its holdings in shares of CVS Health by 8.0% during the third quarter. Iberiabank Corp now owns 15,030 shares of the pharmacy operator’s stock valued at $1,222,000 after acquiring an additional 1,108 shares in the last quarter. Hedge funds and other institutional investors own 80.81% of the company’s stock.

CVS Health Corp (NYSE:CVS) opened at $69.87 on Tuesday. The firm has a market capitalization of $70,780.00, a P/E ratio of 11.84, a price-to-earnings-growth ratio of 1.16 and a beta of 0.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.52 and a current ratio of 1.02. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.00.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. During the same quarter in the previous year, the business earned $1.71 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. equities research analysts expect that CVS Health Corp will post 6.47 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s payout ratio is currently 33.90%.

A number of equities research analysts have recently commented on CVS shares. Jefferies Group set a $86.00 target price on CVS Health and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Mizuho set a $90.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and set a $77.00 price objective on shares of CVS Health in a research report on Friday, October 27th. Loop Capital reaffirmed a “hold” rating on shares of CVS Health in a research report on Friday, October 27th. Finally, Cowen set a $86.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $87.77.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.61% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/cvs-health-corp-cvs-holdings-lifted-by-dai-ichi-life-insurance-company-ltd.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply